The table below shows Xeris Biopharma Holdings, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
-
-
-
-
$49.59M
$20.43M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$31.16M
$25.56M
$22.34M
$20.97M
$25.16M
$20.92M
SG&A
$182.37M
XERS annual revenue (10-K history)
Xeris Biopharma Holdings, Inc. reported annual revenue of $291.85M for fiscal year 2025. That is up 43.7% from $203.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $20.43M (FY 2020) to $291.85M. Figures come from the company's audited annual reports as filed with the SEC.